Posted 25th January 2019 by Joshua Broomfield
In December 2014, a major flood in north-eastern Peninsular Malaysia affected more than 200,000 people leaving them homeless, with no clean water, and sick with diseases including dengue fever, typhoid, leptospirosis and acute gastroenteritis (approximately 30% of flood-affected population). After 6 months, many were still affected by illness including persistent abdominal pain and diarrhoea. We investigated two of the worst flood-affected communities (Figure A) on their microbiota profile and if a probiotic can help. Following are 5 points I have learned from this invaluable experience:
Posted 18th January 2019 by Jane Williams
Recent progress in science pinpoints that the gut-brain axis may be modulated by a class of probiotics called psychobiotics. These progresses shed lights on a new area of research and new ways to treat a broad spectrum of complex central nervous system diseases.
Posted 24th December 2018 by Kate Barlow
2018 has been another big year for the microbiome and probiotics. Investment is at an all-time high with the global probiotics market expected to grow with a compound annual growth rate of 6.5% over the forecast period of 2018-2024, while the microbiome market is predicted to grow from $235.8 million in 2018 to $521.23 million by 2022. 
Posted 22nd October 2018 by Kate Barlow
The Probiotics/Prebiotics Market
Interest in microbiota, specifically in human health and disease, has encouraged consumers to focus on digestive health, which has seen the probiotics and prebiotics market go from strength-to-strength.
As a result, the global probiotics and prebiotics market was valued at approximately USD 40.09 billion in 2017 and is expected to generate revenue of around USD 65.87 billion by end of 2024, growing at a compound annual growth rate of around 7.35% between 2018 and 2024. 
Posted 7th September 2018 by Kate Barlow
Antibiotic use can disrupt your body’s protective microbial barrier and open the door to pathogens and illness. Our research focuses on developing next-generation probiotics that would selectively prevent infection by the bacterium Clostridium difficile, a gastrointestinal pathogen that produces toxins resulting in watery diarrhoea and in severe cases, pseudomembrane colitis, toxemia, sepsis and death.